image
Healthcare - Medical - Diagnostics & Research - NYSE - NL
$ 46.0
0.218 %
$ 10.2 B
Market Cap
102.22
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one QGEN stock under the worst case scenario is HIDDEN Compared to the current market price of 46 USD, Qiagen N.V. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one QGEN stock under the base case scenario is HIDDEN Compared to the current market price of 46 USD, Qiagen N.V. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one QGEN stock under the best case scenario is HIDDEN Compared to the current market price of 46 USD, Qiagen N.V. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
1.97 B REVENUE
-8.23%
445 M OPERATING INCOME
-16.22%
341 M NET INCOME
-19.35%
459 M OPERATING CASH FLOW
-35.76%
-87.7 M INVESTING CASH FLOW
87.94%
-434 M FINANCING CASH FLOW
-244.85%
502 M REVENUE
1.11%
112 M OPERATING INCOME
149.07%
98.1 M NET INCOME
153.45%
182 M OPERATING CASH FLOW
9.44%
-231 M INVESTING CASH FLOW
-1195.27%
486 M FINANCING CASH FLOW
481.18%
Balance Sheet Qiagen N.V.
image
Current Assets 2.15 B
Cash & Short-Term Investments 1.06 B
Receivables 516 M
Other Current Assets 574 M
Non-Current Assets 3.97 B
Long-Term Investments 29.5 M
PP&E 870 M
Other Non-Current Assets 3.07 B
Current Liabilities 1.08 B
Accounts Payable 84.2 M
Short-Term Debt 610 M
Other Current Liabilities 385 M
Non-Current Liabilities 1.23 B
Long-Term Debt 1 B
Other Non-Current Liabilities 227 M
EFFICIENCY
Earnings Waterfall Qiagen N.V.
image
Revenue 1.97 B
Cost Of Revenue 742 M
Gross Profit 1.22 B
Operating Expenses 778 M
Operating Income 445 M
Other Expenses 104 M
Net Income 341 M
RATIOS
62.23% GROSS MARGIN
62.23%
22.66% OPERATING MARGIN
22.66%
17.37% NET MARGIN
17.37%
8.96% ROE
8.96%
5.58% ROA
5.58%
6.65% ROIC
6.65%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Qiagen N.V.
image
Net Income 341 M
Depreciation & Amortization 205 M
Capital Expenditures -163 M
Stock-Based Compensation 47.1 M
Change in Working Capital -187 M
Others -22.7 M
Free Cash Flow 297 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Qiagen N.V.
image
Wall Street analysts predict an average 1-year price target for QGEN of $48.3 , with forecasts ranging from a low of $46 to a high of $50 .
QGEN Lowest Price Target Wall Street Target
46 USD 0.00%
QGEN Average Price Target Wall Street Target
48.3 USD 5.07%
QGEN Highest Price Target Wall Street Target
50 USD 8.70%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
1.32 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Qiagen N.V.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
New Product Offerings Support QIAGEN's Shares Amid Currency Woes To support internal growth, QIAGEN is investing heavily in R&D for menu expansion of its key platforms. zacks.com - 2 weeks ago
Here's Why Qiagen (QGEN) is a Strong Momentum Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com - 2 weeks ago
Why Qiagen (QGEN) is a Top Momentum Stock for the Long-Term The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. zacks.com - 1 month ago
QIAGEN Stock Gains Following the Latest Launch of IPA Interpret QGEN announces the launch of IPA Interpret to extend the analysis capabilities of a human-curated knowledge base with AI technology. zacks.com - 1 month ago
QIAGEN Launches AI-Extension of Ingenuity Pathway Analysis for Automatic Interpretation of Biological Data REDWOOD CITY, Calif. & VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN, Frankfurt Prime Standard: QIA) today announced the launch of Ingenuity Pathway Analysis (IPA) Interpret, a new feature designed to simplify and accelerate the interpretation of complex biological data. Leveraging AI technology, IPA Interpret helps distill complex differential expression analyses into actionable insights, helping researchers understand which genes are involved in a disease, a biological process o. businesswire.com - 1 month ago
QIAGEN Stock Might Rise Following 1000 EZ2 Connect Placements QGEN achieves milestone with more than 1,000 EZ2 Connect placements worldwide, contributing to a global installed base of over 5,500 EZ series instruments. zacks.com - 1 month ago
QIAGEN Reaches Milestone With Over 1,000 Placements of EZ2 Connect Sample Preparation Instrument, Driving Laboratory Automation VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has reached a significant milestone with over 1,000 placements of the EZ2 Connect automated sample preparation instrument, an advancement of the EZ1 instrument line. Launched in 2021, the updated EZ2 Connect has quickly become a market-leading instrument for sample preparation and data management, contributing to a total of more than 5,500 EZ series instruments placed globally. EZ2 Connect. businesswire.com - 1 month ago
Should You Continue to Retain QIAGEN Stock in Your Portfolio Now? QGEN's robust expansion of its testing menu and potential in molecular diagnostics bode well for investors. zacks.com - 1 month ago
Here's Why Qiagen (QGEN) is a Strong Value Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com - 1 month ago
QGEN Stock to Gain From Expanding QIAstat-Dx With New Barcelona Site QIAGEN's new Barcelona site is set to drive QIAstat-Dx's growth in infectious diseases and precision medicine testing. zacks.com - 1 month ago
QGEN Stock Dips Despite Launch of Customized dPCR Assay Design Tools QIAGEN introduces two new customizable dPCR assay design tools featuring advanced design algorithms tailored for diverse microbial applications and custom NGS panels. zacks.com - 1 month ago
QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing BARCELONA, Spain & VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to move its QIAstat-Dx operations within the Barcelona area to a new site in Esplugues de Llobregat as part of a multi-year investment to strengthen this business. Set to open in early 2026, the new site will cover the entire value chain for the QIAstat-Dx system, which is used for syndromic testing to identify the cause of an illness – especially in the areas of. businesswire.com - 1 month ago
8. Profile Summary

Qiagen N.V. QGEN

image
COUNTRY NL
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 10.2 B
Dividend Yield 0.00%
Description QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
Contact Hulsterweg 82, Venlo, 5912 PL https://www.qiagen.com
IPO Date June 28, 1996
Employees 5800
Officers Mr. John Gilardi Vice President of Corporate Communications & Investor Relations Mr. Jean-Pascal Viola Senior Vice President & Head of Corporate Strategy and Business Development Dr. Thomas Schweins Senior Vice President of Life Science Business Area Dr. Roland Sackers Chief Financial Officer, MD & Member of Management Board Dr. Thomas Theuringer Senior Director & Head of External Communications Dr. Jonathan G. Sheldon Ph.D. Senior Vice President & Head of the QIAGEN Digital Insights Business Area Ms. Stephany Foster Senior Vice President & Head of Human Resources Dr. Dominic John Vice President of Marketing & Product Management Mr. Thierry Bernard Chief Executive Officer, MD & Member of Management Board Mr. Antonio Santos Senior Vice President & Head of Global Operations